Neutral
●
Business Wire
●
4 months ago
OSAKA, Japan--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) announced the presentation of data from the randomized, double-blind, placebo-controlled, Phase 2 study of ONO-2808（ONO-2808-03 study）for the treatment of multiple system atrophy (MSA) at the 7th World Parkinson Congress, held from May 24 to May 27, 2026, in Phoenix,...